Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection

被引:27
作者
Jamshidi, Y. [2 ]
Moreton, M. [3 ]
McKeown, D. A. [3 ]
Andrews, S. [4 ]
Nithiyananthan, T. [2 ]
Tinworth, L. [2 ]
Holt, D. W. [3 ]
Sadiq, S. T. [1 ,4 ]
机构
[1] Univ London, Div Clin Sci, Ctr Infect & Immun, London SW17 0RE, England
[2] Univ London, Div Biomed Sci, London SW17 0RE, England
[3] Univ London, Analyt Unit, London SW17 0RE, England
[4] St Georges Healthcare NHS Trust, Dept GU Med, London, England
关键词
Bantu; Nilotic; efavirenz; pharmacogenetics; antiretrovirals; HIV; genetic diversity; PAPUA-NEW-GUINEA; ANTIRETROVIRAL THERAPY; PLASMA-CONCENTRATIONS; WEST-AFRICA; POLYMORPHISM; INDIVIDUALS; METABOLISM; PREVALENCE; EXPRESSION; CYP2B6-ASTERISK-6;
D O I
10.1093/jac/dkq369
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To determine differences in CYP2B6 loss of function (LoF) single nucleotide polymorphisms (SNPs) and haplotypes between Zimbabweans and Ugandans, and within Ugandan populations (Bantu and Nilotic). Genetic epidemiological study enrolling adult black African Ugandan and Zimbabwean patients attending a UK HIV-1 clinic, irrespective of antiretroviral therapy status. Genomic DNA was extracted from whole blood and the presence of CYP2B6 alleles was determined by direct sequencing of all nine exons of the CYP2B6 gene. Blood was also collected, where appropriate, for determination of efavirenz concentrations. Frequency of SNPs in all patients and LoF haplotype frequencies were calculated. The relationship between the number of LoF haplotype alleles possessed and efavirenz trough concentration (ETC) was determined. Thirty-six Zimbabweans and 74 Ugandans (58 Bantu and 16 Nilotic) were recruited. The definite haplotypes determined were *6, *18, *20 and *27 as LoF and *4 as gain of function. Among those with definite genotypes, the frequency of LoF alleles was 65% [95% confidence interval (95% CI): 51-80] of Zimbabweans versus 22% (95% CI: 12-31) of Ugandan Bantus (P = 10(-6)) and versus 39% (95% CI: 14-64) of Ugandan Nilotics (P = 0.09). Among the 19 patients with definite genotype and with available ETCs, log ETCs were associated with a greater number of LoF haplotype alleles [848 ng/mL (n = 12), 1069 ng/mL (n = 4) and 1813 ng/mL (n = 3) for 0, 1 or 2 LoF haplotypes, respectively (P = 0.016)]. Among Zimbabweans, LoF haplotypes constitute the majority of CYP2B6 alleles and are significantly higher in prevalence compared with Ugandans. Frequencies of LoF haplotypes and SNPs in Ugandan Nilotics appear to lie between those of Zimbabweans and Ugandan Bantus. These findings may have relevance to pharmacokinetics and dosing of efavirenz in African populations.
引用
收藏
页码:2614 / 2619
页数:6
相关论文
共 26 条
[1]  
[Anonymous], 2008, LANCET, V372, P293
[2]   Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals [J].
Arab-Alameddine, M. ;
Di Iulio, J. ;
Buclin, T. ;
Rotger, M. ;
Lubomirov, R. ;
Cavassini, M. ;
Fayet, A. ;
Decosterd, L. A. ;
Eap, C. B. ;
Biollaz, J. ;
Telenti, A. ;
Csajka, C. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) :485-494
[3]   Genetic and Demographic Implications of the Bantu Expansion: Insights from Human Paternal Lineages [J].
Berniell-Lee, Gemma ;
Calafell, Francesc ;
Bosch, Elena ;
Heyer, Evelyne ;
Sica, Lucas ;
Mouguiama-Daouda, Patrick ;
van der Veen, Lolke ;
Hombert, Jean-Marie ;
Quintana-Murci, Lluis ;
Comas, David .
MOLECULAR BIOLOGY AND EVOLUTION, 2009, 26 (07) :1581-1589
[4]   Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort [J].
Carr, Daniel F. ;
la Porte, Charles J. L. ;
Pirmohamed, Munir ;
Owen, Andrew ;
Cortes, Claudia P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (09) :1889-1893
[5]   Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro [J].
Desta, Zeruesenay ;
Saussele, Tanja ;
Ward, Bryan ;
Blievernicht, Julia ;
Li, Lang ;
Klein, Kathrin ;
Flockhart, DavidA ;
Zanger, Ulrich M. .
PHARMACOGENOMICS, 2007, 8 (06) :547-558
[6]   In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function [J].
di Iulio, Julia ;
Fayet, Aurelie ;
Arab-Alameddine, Mona ;
Rotger, Margalida ;
Lubomirov, Rubin ;
Cavassini, Matthias ;
Furrer, Hansjakob ;
Guenthard, Huldrych F. ;
Colombo, Sara ;
Csajka, Chantal ;
Eap, Chin B. ;
Decosterd, Laurent A. ;
Telenti, Amalio .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (04) :300-309
[7]  
Haas DW, 2004, AIDS, V18, P2391
[8]   Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver [J].
Hofmann, Marco H. ;
Blievernicht, Julia K. ;
Klein, Kathrin ;
Saussele, Tanja ;
Schaeffeler, Elke ;
Schwab, Matthias ;
Zanger, Ulrich M. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (01) :284-292
[9]   Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 [J].
Kirchheiner, J ;
Klein, C ;
Meineke, I ;
Sasse, J ;
Zanger, UM ;
Mürdter, TE ;
Roots, I ;
Brockmöller, J .
PHARMACOGENETICS, 2003, 13 (10) :619-626
[10]   Genetic variability of CYP2B6 in populations of African and Asian origin:: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz [J].
Klein, K ;
Lang, T ;
Saussele, T ;
Barbosa-Sicard, E ;
Schunck, WH ;
Eichelbaum, M ;
Schwab, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (12) :861-873